275 related articles for article (PubMed ID: 17349451)
1. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
[TBL] [Abstract][Full Text] [Related]
2. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.
Kuehne FC; Bethe U; Freedberg K; Goldie SJ
Arch Intern Med; 2002 Dec 9-23; 162(22):2545-56. PubMed ID: 12456226
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
9. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
12. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
Nakamura J; Kobayashi K; Toyabe S; Aoyagi Y; Akazawa K
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):733-9. PubMed ID: 17700257
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
15. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
Sagmeister M; Wong JB; Mullhaupt B; Renner EL
Eur J Gastroenterol Hepatol; 2001 May; 13(5):483-8. PubMed ID: 11396525
[TBL] [Abstract][Full Text] [Related]
16. Therapy of chronic hepatitis C in the setting of HIV co-infection.
Michielsen P; Bottieau E
Acta Gastroenterol Belg; 2005; 68(1):86-91. PubMed ID: 15832592
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N
Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498
[TBL] [Abstract][Full Text] [Related]
18. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
Wong JB; Davis GL; McHutchison JG; Manns MP; Albrecht JK;
Am J Gastroenterol; 2003 Nov; 98(11):2354-62. PubMed ID: 14638334
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
20. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin HF; Cave CB; Waugh NR; Price A; Gabbay J
Int J Technol Assess Health Care; 2005; 21(1):47-54. PubMed ID: 15736514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
